Acurx Pharmaceuticals, Inc.
ACXP
$3.88
-$0.265-6.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.75M | 1.55M | 1.96M | 1.62M | 2.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.27M | 2.15M | 2.78M | 2.82M | 4.12M |
| Operating Income | -2.27M | -2.15M | -2.78M | -2.82M | -4.12M |
| Income Before Tax | -2.25M | -2.15M | -2.78M | -2.82M | -4.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.25M | -2.15M | -2.78M | -2.82M | -4.12M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.25M | -2.15M | -2.78M | -2.82M | -4.12M |
| EBIT | -2.27M | -2.15M | -2.78M | -2.82M | -4.12M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.89 | -2.15 | -3.29 | -3.45 | -5.21 |
| Normalized Basic EPS | -1.18 | -1.34 | -2.05 | -2.16 | -3.26 |
| EPS Diluted | -1.89 | -2.15 | -3.29 | -3.45 | -5.21 |
| Normalized Diluted EPS | -1.18 | -1.34 | -2.05 | -2.16 | -3.26 |
| Average Basic Shares Outstanding | 1.19M | 1.00M | 846.50K | 818.20K | 791.20K |
| Average Diluted Shares Outstanding | 1.19M | 1.00M | 846.50K | 818.20K | 791.20K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |